Validation and Refinement Of The Disease Risk Index For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of 13,131 Patients From The Center For International Blood & Marrow Transplant Research
Philippe A, Haesook T, Brent R et al.
Key Points:
Authors propose Disease Risk Index (DRI) to evaluate HSCT outcome.
13,131 adult patients who underwent HSCT for hematological malignancies included.
Stratified patients into 4 groups with 2y OS of 64% in the low-risk, 51% in the intermediate, 34% in the high, and 24% in very high risk group (p<0.0001).
Implications:
- DRI was most important prognostic factor, with a hazard ratio (HR) for mortality of 1.5, 2.3 and 3.0 for intermediate, high and very high risk groups respectively.
View the original abstract on the ASH website.
